Europe Human Insulin Market Introduction and Overview
According to SPER Market Research, the Europe Human Insulin Market is estimated to reach USD XX billion by 2033 with a CAGR of 1.7%.
The report includes an in-depth analysis of the Europe Human Insulin Market, including market size and trends, product mix, Applications, and supplier analysis. Insulin, a protein hormone, is well known for helping people control their blood sugar levels when their bodies are unable to make enough of it. Insulin increases the absorption of glucose into fatty tissues and muscles, lowering blood glucose levels. It governs the blood's levels of glucose, or sugar, as well as the body's intake of amino acids and the metabolism of lipids, proteins, and carbs. Diabetes is a long-term medical illness characterised by an excess of blood sugar in the bloodstream due to either insufficient insulin production by the body or a lack of cell response to it. This condition necessitates the daily administration of such hormone and might result in health issues like heart disease, vision loss, etc.
- January 2023: Abbott and Sanofi collaborated to provide solutions that integrate insulin dosage data from Sanofi's diabetes care devices with FreeStyle Libre technology. People with diabetes and medical practitioners will be able to make more informed decisions about medication, diet, and lifestyle choices because to this collaboration.
- August 2022: The US FDA and the European Medicines Agency (EMA) provided extra funding to Oramed's Oralis project in order to conduct a Phase III clinical trial of Oralis, which aimed to demonstrate the oral drug's efficacy in glycaemic management in patients with type 2 diabetes.
- June 2021: In comparison to premixed insulin, Sanofi reported that the new long-acting human insulin analogue Soliqua demonstrated better blood sugar control without causing weight gain.
Market Opportunities and Challenges
Europe stands as the second-largest market for human insulin globally, marked by increased product launches from key regional players. This has facilitated the introduction of cost-effective human insulin products, fostering accessibility in European nations. The region is witnessing heightened awareness of human insulin due to the escalating prevalence of diabetes and elevated blood sugar levels. Human insulin therapy has become more popular as a result of rising knowledge and the general availability of reasonably priced goods from major producers, which has expanded the market. Additionally, the extensive presence and efficient distribution channels of major regional players are anticipated to further boost market growth. Increased R&D investments and the focus on technologically advanced insulin products underscore a promising trajectory for the market in Europe and its global market share.
On the other hand, due to the expensive cost of current conventional human insulin treatments, there is a growing desire among the population for alternative insulin solutions. For the purpose of treating diabetes in the area, a number of significant firms are presently concentrating on developing and introducing insulin substitute biosimilars. Therefore, throughout the projection period, the market would be restrained by the increasing release of substitute insulin treatments, such as biosimilar insulins. It is also anticipated that the increase in production costs for insulin medications and delivery systems will hinder the market's expansion for these products in the human population throughout the forecast period.
Market Competitive Landscape
The European human insulin market is extremely consolidated with three large manufacturers who are also present in the global market. The remaining manufacturers are restricted to competing with other regional or local manufacturers. In recent times, firms have strengthened their market position through mergers and acquisitions among themselves. Boehringer Ingelheim and Eli Lilly have partnered to develop and market Abasaglar, also known as Insulin Glargine. The major players in the Europe Human Insulin market include: ADOCIA, B. Braun Melsungen AG, Biocon, BIOTON S.A., Eli Lilly and Company, Lupin, Novo Nordisk A/S, Sanofi, WOCKHARDT, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Type, By Diabetes Type, By Distribution Channel
|
| Regions covered | France, Germany, Italy, Scandinavia, Spain, U.K., and rest of Europe
|
| Companies Covered | ADOCIA, B. Braun Melsungen AG, Biocon, BIOTON S.A., Eli Lilly and Company, Lupin, Novo Nordisk A/S, Sanofi, WOCKHARDT, Others |
COVID-19 Impact on Europe Human Insulin Market
The COVID-19 virus first appeared in December 2019 and has since spread to almost every nation on the earth, leading the World Health Organisation (WHO) to declare a public health emergency. Because of COVID-19, the supply chain for the raw materials required to produce human insulin medications and delivery systems has been disrupted in a number of nations. Furthermore, because manufacturers of these pharmaceuticals and devices have limited output, the market for human insulin is contracting as a result of the outbreak. Therefore, it is anticipated that COVID 19 will have a major impact on the market for human insulin delivery systems and medications.
Key Target Audience:
- Health Insurers and Payers
- Healthcare Professionals
- People with Diabetes (PWD)
- Pharmaceutical Companies
- Pharmacists
- Public Health Organizations
- Researchers and Scientists
- Others
Our in-depth analysis of the Europe Human Insulin Market includes the following segments:
|
By Type:
|
Analogue Insulin
Traditional Human Insulin
|
|
By Diabetes Type:
|
Diabetes 1
Diabetes 2
|
|
By Distribution Channel:
|
Hospital Pharmacies
Retail & Online Pharmacies
|
Key Topics Covered in the Report:
- Europe Human Insulin Market Size (FY’2023-FY’2033)
- Overview of Europe Human Insulin Market
- Segmentation of Europe Human Insulin Market By Type (Analogue Insulin, Traditional Human Insulin)
- Segmentation of Europe Human Insulin Market By Diabetes Type (Diabetes 1, Diabetes 2)
- Segmentation of Europe Human Insulin Market By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies)
- Statistical Snap of Europe Human Insulin Market
- Expansion Analysis of Europe Human Insulin Market
- Problems and Obstacles in Europe Human Insulin Market
- Competitive Landscape in the Europe Human Insulin Market
- Impact of COVID-19 and Demonetization on Europe Human Insulin Market
- Details on Current Investment in Europe Human Insulin Market
- Competitive Analysis of Europe Human Insulin Market
- Prominent Players in the Europe Human Insulin Market
- SWOT Analysis of Europe Human Insulin Market
- Europe Human Insulin Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data Source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Human Insulin Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Human Insulin Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Human Insulin Market
7. Europe Human Insulin Market, By Type (USD Million)
7.1. Europe Human Insulin Market Value Share and Forecast, By Type, 2023-2033
7.2. Analogue Insulin
7.2.1. Fast-acting
7.2.2. Long-acting
7.2.3. Premix
7.3. Traditional Human Insulin
7.3.1. Fast-acting
7.3.2. Long-acting + Intermediate
7.3.3. Premix
7.3.4. Short-acting
8. Europe Human Insulin Market, By Diabetes Type (USD Million)
8.1. Europe Human Insulin Market Value Share and Forecast, By Diabetes Type, 2023-2033
8.2. Diabetes 1
8.3. Diabetes 2
9. Europe Human Insulin Market, By Distribution Channel (USD Million)
9.1. Europe Human Insulin Market Value Share and Forecast, By Distribution Channel, 2023-2033
9.2. Hospital Pharmacies
9.3. Retail & Online Pharmacies
10. Europe Human Insulin Market Forecast, 2019-2033 (USD Million)
10.1. Europe Human Insulin Market Size and Market Share
11. Europe Human Insulin Market, By Type, 2019-2033 (USD Million)
11.1. Europe Human Insulin Market Size and Market Share By Type (2019-2026)
11.2. Europe Human Insulin Market Size and Market Share By Type (2027-2033)
12. Europe Human Insulin Market, By Diabetes Type, 2019-2033 (USD Million)
12.1. Europe Human Insulin Market Size and Market Share By Diabetes Type (2019-2026)
12.2. Europe Human Insulin Market Size and Market Share By Diabetes Type (2027-2033)
13. Europe Human Insulin Market, By Distribution Channel, 2019-2033 (USD Million)
13.1. Europe Human Insulin Market Size and Market Share By Distribution Channel (2019-2026)
13.2. Europe Human Insulin Market Size and Market Share By Distribution Channel (2027-2033)
14. Europe Human Insulin Market, By Region, 2019-2033 (USD Million)
14.1. Europe Human Insulin Market Size and Market Share By Region (2019-2026)
14.2. Europe Human Insulin Market Size and Market Share By Region (2027-2033)
14.3. France
14.4. Germany
14.5. Italy
14.6. Scandinavia
14.7. Spain
14.8. U.K.
14.9. Rest of Europe
15. Company Profile
15.1. ADOCIA
15.1.1. Company details
15.1.2. Financial outlook
15.1.3. Product summary
15.1.4. Recent developments
15.2. B. Braun Melsungen AG
15.2.1. Company details
15.2.2. Financial outlook
15.2.3. Product summary
15.2.4. Recent developments
15.3. Biocon
15.3.1. Company details
15.3.2. Financial outlook
15.3.3. Product summary
15.3.4. Recent developments
15.4. BIOTON S.A.
15.4.1. Company details
15.4.2. Financial outlook
15.4.3. Product summary
15.4.4. Recent developments
15.5. Eli Lilly and Company
15.5.1. Company details
15.5.2. Financial outlook
15.5.3. Product summary
15.5.4. Recent developments
15.6. Lupin
15.6.1. Company details
15.6.2. Financial outlook
15.6.3. Product summary
15.6.4. Recent developments
15.7. Novo Nordisk A/S
15.7.1. Company details
15.7.2. Financial outlook
15.7.3. Product summary
15.7.4. Recent developments
15.8. Sanofi
15.8.1. Company details
15.8.2. Financial outlook
15.8.3. Product summary
15.8.4. Recent developments
15.9. WOCKHARDT
15.9.1. Company details
15.9.2. Financial outlook
15.9.3. Product summary
15.9.4. Recent developments
15.10. Others
16. List of Abbreviations
17. Reference Links
18. Conclusion
19. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
